Type 2 diabetes mellitus is a risk factor for incident heart failure and increases the risk of
morbidity and mortality in patients with established disease. Secular trends in the …

Epidemiologic and clinical data from the last 2 decades have shown that the prevalence of
heart failure in diabetes is very high, and the prognosis for patients with heart failure is …

Recent randomized trials have compared the newer antidiabetic agents to treatments
involving sulfonylureas, drugs associated with increased cardiovascular risks and mortality …

ABSTRACT Introduction: Dipeptidyl peptidase-4 inhibitors (DPP-4is) are generally
considered as glucose-lowering agents with a safe profile in type 2 diabetes. Areas covered …

Importance Results of clinical trials suggest that canagliflozin, a sodium-glucose
cotransporter 2 (SGLT-2) inhibitor for treating type 2 diabetes, may be associated with lower …

Type 2 diabetes mellitus is a risk factor for incident heart failure and increases the risk of
morbidity and mortality in patients with established disease. Secular trends in the …

Background Randomized controlled trials showed that newer glucose‐lowering agents are
cardioprotective, but most participants were men. It is unknown whether benefits are similar …

Aims To investigate the association of novel oral glucose‐lowering drugs (GLDs), compared
with that of insulin, with risk of all‐cause mortality, cardiovascular disease (CVD) and severe …

Abstract Purpose of Review The global prevalence of “diabesity”—diabetes related to
obesity—is increasing steadily over the past few decades because of the obesity epidemic …

Context: Although there is evidence to support the beneficial effects of statins on major
cardiovascular events, few studies address the protective effect of statins on limb outcome …